Estratégias farmacológicas e procedimentais para prevenir pancreatite pós-ERCP: uma revisão geral de meta-análises de ensaios clínicos randomizados
GastroenterologiaResumo original em inglês
O que aconteceu
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common complication following ERCP, and its prevention remains a major concern for biliopancreatic endoscopists. This umbrella review aims to assess existing meta-analytic evidence on the effectiveness of pharmacological interventions (PIs) and procedural technical modifications (PTMs) in reducing the incidence and severity of PEP
We searched multiple databases to identify meta-analyses of randomized controlled trials (RCTs) that assessed the impacts of PIs or PTMs on the incidence and severity of PEP, from database inception to September 24, 2024. Evidence credibility was classified based on pre-specified criteria as: convincing (Class I), highly suggestive (Class II), suggestive (Class III), weak (Class IV), or non-significant evidence. Furthermore, the GRADE approach was employed to assess the quality of the evidence, categorizing it into four levels: high, moderate, low, and very low
O que encontraram
A review of 47 meta-analyses (137,391 participants; 25 on PIs, 22 on PTMs) identified five PIs with suggestive evidence for PEP prevention: indomethacin (odds ratio [OR] 0.52, 95% confidence interval [CI] 0.39–0.71), epinephrine (risk ratio [RR] 0.34, 95% CI 0.18–0.62), nafamostat mesylate (RR 0.50, 0.38–0.66), NSAIDs (RR 0.65, 0.52–0.81), and aggressive hydration (OR 0.40, 0.26–0.63). For PTMs, one intervention was classified as highly suggestive evidence: pancreatic stent placement (RR 0.37, 0.27–0.51), while guidewire-assisted cannulation was suggestive (RR 0.51, 0.36–0.72). For high-risk patients, both indomethacin (RR 0.46, 0.32–0.65) and pancreatic stent placement (RR 0.41, 0.30–0.56) were suggestive. No interventions exceeded Class III evidence for preventing moderate to severe PEP
Por que isso importa
Pancreatic stent placement and NSAIDs, such as indomethacin, have been confirmed as effective measures for PEP prevention in both unselected and high-risk patients
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
Pharmacological and procedural strategies to prevent post-ERCP pancreatitis: an umbrella review of meta-analyses of randomized controlled trials
Mengruo Jiang, Liqi Sun, Lisi Peng, Deyu Zhang, Chao Liu, Lixiang Wang, Yuwei Sun, Zhendong Jin, Zhaoshen Li, Saif Ullah et al.
Descritores MeSH
- Cholangiopancreatography, Endoscopic Retrograde
- Pancreatitis
- Humans
- Indomethacin
- Meta-Analysis as Topic
- Randomized Controlled Trials as Topic
Veja também
Estudos relacionados
- Efficacy of indomethacin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A comprehensive meta-analysis of randomized controlled trials
- Rectal Indomethacin in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: An Updated Meta-Analysis with Trial Sequential Analysis
- Retal Anti-Inflamatórios Não Esteroidais, Hidratação Agressiva com Solução de Ringer Lactada, Somatostatina ou Combinações para Profilaxia Pancreatite Aguda Pós-ERCP: Uma Meta-Análise de Rede
- Rectal Diclofenac Versus Indomethacin in Preventing Post-ERCP Pancreatitis: A Systematic Review and Meta-Analysis
- Systematic review and meta-analysis: no evidence that low-dose non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP)
- Nitroglycerin combined with NSAIDs for prevention of post-ERCP pancreatitis: A meta-analysis of prospective, randomized, controlled trials